Articles tagged with Breast Carcinoma
A new gene classifier has been developed to predict the risk of breast pre-cancer progression in women with ductal carcinoma in situ (DCIS). The study identified 812 genes associated with cancer progression and found that most DCIS cancers were at low risk for recurrence or progression.
Researchers at the University of Basel have successfully differentiated triple-negative breast cancer cells into normal-like cells, opening a new avenue for treatment. The breakthrough uses inhibitors of polo-like kinase 1 to induce estrogen receptor expression, leading to reduced cell growth and tumorigenicity.
Researchers analyzed germline variants in breast cancer patients to identify their role in metastasis development. The study found that host genetic makeup contributes to metastasis through dysregulation of gene expression, promoting the dispersion of metastatic seeds and establishing a conducive environment for their growth.
Researchers at Johns Hopkins Kimmel Cancer Center developed a targeted immunotoxin that delivers into breast ducts, eliminating visible and invisible precancerous lesions in laboratory studies. The treatment showed strong cancer-killing effects in all cell lines and was well-tolerated in mouse models.
A population-based study found that patients with estrogen receptor-positive breast cancer who experienced hot flashes while on adjuvant hormone therapy had worse outcomes and a higher risk of early treatment discontinuation. The study suggests that managing side effects may not be enough to prevent treatment discontinuation, highlight...
Researchers at Mount Sinai have discovered a previously unknown mechanism by which not-yet-malignant breast cancer cells can travel to other organs and 'turn on' to become metastatic. The study identified potential diagnostic biomarkers, including the transcription factor NR2F1, that could help predict relapse.
Researchers have discovered 23 proteins in breast milk that could indicate breast cancer, paving the way for a potential blood test. The study's findings, if confirmed, may enable earlier diagnosis and improve survival rates.
A new study suggests that cardamonin, a compound from the cardamom spice, can kill triple-negative breast cancer cells and reduce PD-L1 expression. The findings hold promise for improving cancer therapy without severe side effects.
A study analyzing blood samples from premenopausal women with breast cancer found high levels of inflammatory markers and low antioxidant levels. These findings may reveal a new diagnostic tool for the disease, with implications for identifying early stages and improving treatment outcomes.
The American Roentgen Ray Society recognizes Drs. Nguyen, Beheshtian, Harfouch, and Hashiba for their outstanding research and education contributions to the field of radiology. The awards honor the candidates' scientific merit and potential impact on imaging and allied sciences research.
Researchers at Tufts University have found that manipulating voltage patterns in tumor cells can significantly reduce tumor cell invasion and metastasis in animal models. Using FDA-approved ion channel blockers, they were able to normalize cell voltages, decrease tumor growth, and limit the spread of cancer cells.
Researchers identified DSS1 as a critical protein in breast cancer progression and found that depleting it makes cancer cells more responsive to lower doses of anti-cancer drugs. This technique may reduce drug-induced side effects in breast cancer patients, providing a safer treatment option.
Researchers found that TMEM165 expression levels alter N-linked glycosylation, promoting the invasion and growth of breast cancer cells. This study suggests a novel role for TMEM165 as a driver of tumor invasion and identifies it as a potential biomarker for breast carcinoma.
A study found that pathologists' diagnoses for breast biopsies have a high rate of disagreement, especially for cases of atypical hyperplasia and ductal carcinoma in situ. The researchers suggest that obtaining a second opinion for these cases could help reduce unnecessary treatment.
A study found that over 10 years, 30.8% of women had diagnostic mammograms, while 61.5% underwent ipsilateral invasive procedures following BCS. The high rates may be due to concerns about recurrence, and the authors highlight the need for better prognostic biomarkers to minimize overtreatment.
A study found that lobular breast cancer (ILC) and ductal breast cancer (IDC) have similar success rates for breast-conserving therapy. ILC patients had larger tumors, but the success rate did not differ between groups.
Women with hereditary non-BRCA breast cancer face a significantly higher risk of developing second primary breast cancers (CBCs), with probabilities ranging from 1.9% to 27.3% over 20 years. Adjuvant hormonal therapy can lower this risk, whereas chemotherapy has no apparent effect.
A study of 1,036 women with ductal carcinoma in situ (DCIS) diagnosed at age 40 or older found that those with high-nuclear-grade lesions had a higher risk of invasive cancer recurrence. Women treated by lumpectomy alone who experienced initial palpation-detected lesions also faced a greater risk of recurrence.
Researchers identified a novel gene, mammaglobin (MG), expressed only in breast cancer tissue. MG was found to be present in 81% of breast cancers and has potential applications for early detection and identification of metastases.
A new study by Yale researchers found that many risk factors for early breast cancer are also linked to advanced breast cancer. The study, which included over 1,000 women diagnosed with early breast cancer, revealed a correlation between family history, previous breast biopsy, and older age at menopause.